New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Sanofi (SNY) Acquires Tidal Therapeutics for $160M Upfront and Up to $310M in Milestones
-
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
-
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
-
Google-backed TAE Technologies raises $280 million from new, existing investors
-
CIT GAP Funds Invests in Floorwire to Give Commercial Owners Control of Architectural Data
-
Patreon Fuels the Future of the Creator Economy with $155 Million in Additional Funding
-
Creators' platform Patreon valued $4 billion in latest funding round
-
OmniSci Announces Multiple Opportunities To Accelerate Geospatial, GPU Database Knowledge At GTC 2021, April 12-16
-
Announcing Zero Trust Authentication for Managed Devices and BYOD
-
Announcing Zero Trust Authentication for Managed Devices and BYOD
-
ThreatQuotient Closes $22.5 Million in New Financing to Accelerate Innovation and Execution
-
Long Hill Capital Closes On $300M for Third Fund to Invest in Healthcare and Longevity Sectors in China
-
New Wave Foods® Launches Its Plant-Based Shrimp to Foodservice Companies throughout the U.S.
-
Form SC 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
-
CIT GAP Funds Invests in Linebird to Bring the Unmanned Systems Revolution to High Voltage Power Lines
-
Robinhood, at the heart of retail trading frenzy, files for own IPO
-
Study Shows New Relational Digital Therapeutic Significantly Reduced Problematic Substance Use During Pandemic
-
5th Stanford Drug Discovery Symposium (SDDS 2021) held virtually this year! April 19 - 20, 2021. Free registration!
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Oppenheimer & Co. Inc. Successfully Concludes 31st Annual Healthcare Conference
-
Lumos Pharma Inc. (NASDAQ: LUMO) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
-
CIT GAP Funds Invests in AtWork Systems to Support SMBs with Solutions for Streamlined Business Operations
-
Strive Health Raises $140 Million Led by Alphabet’s CapitalG to Tackle $410 Billion of Unmanaged Kidney Disease Spend
-
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
CIT GAP Funds Makes Follow-On Investment in RoundlyX to Help Users Better Manage Digital Asset Portfolios
-
Form SC 13D/A TREVENA INC Filed by: New Enterprise Associates 12, Limited Partnership
-
Form SC 13D/A Allakos Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A DZS INC. Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Form SC 13D/A Tracon Pharmaceuticals, Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Viracta Therapeutics, Filed by: New Enterprise Associates 12, Limited Partnership
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Quantum Computing Company IonQ to Merge with SPAC dMY Technology Group, Inc. III (DMYI)
-
IonQ To Become The First Publicly Traded Pure-Play Quantum Computing Company
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
-
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
-
Résultats annuels 2020 : Avancées majeures dans la NASH et visibilité financière significativement étendue suite au succès de l’introduction en bourse aux États Unis
-
Lumos Pharma (LUMO) Says Data Supporting Use of Predictive Enrichment Markers for its LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use
-
OmniSci Launches Free Edition of Platform to Democratize the Power of Accelerated Analytics
-
Humana and the University of Houston Announce New Value-based Care Specialization Program
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting

